Detailed Narrative
Robust Q2 FY26 Performance with Strong YoY Growth
Advanced Enzyme Technologies delivered a strong Q2 FY26, with consolidated revenue reaching INR 1,845 million, marking a 26% year-on-year increase. EBITDA surged by 42% YoY to INR 601 million, achieving a healthy margin of 33%. Profit after tax also saw significant growth, up 34% YoY to INR 447 million, with PAT margins at 24%. This performance reflects a continuation of the company's growth trajectory across its business segments.
Segmental Performance Driven by Human Healthcare and Specialized Manufacturing
The Human Healthcare segment, contributing 66% of total revenues, grew 22% YoY to INR 1,212 million, primarily fueled by higher sales in Pharma/API and Nutritional businesses. The Specialized Manufacturing segment showed the strongest growth, increasing 54% YoY to INR 185 million. Bioprocessing also recorded a 52% YoY growth, largely due to a 77% YoY increase in its food business. Animal Healthcare, however, saw a 26% QoQ decline despite a 6% YoY increase.
US Market Faces Tariff Headwinds and Slowness
The US market experienced a 4% decline in H1 FY26 compared to the previous year, primarily due to ongoing tariff issues and a general market slowdown🌐. Management estimates a potential 2% impact on EBITDA if tariffs are fully absorbed, translating to INR 10-11 crore on EBITDA and INR 7-8 crore on PAT. The company is exploring mitigation strategies but has not yet disclosed specific plans, indicating a 'wait and watch' approach amidst global uncertainties.
Strategic R&D Investments and International Expansion Initiatives
Advanced Enzyme is investing in a new R&D center, expected to be partially active by the end of FY26, aiming to significantly increase its R&D capacity. R&D spending for Q2 FY26 totaled INR 80 million, representing 3% of revenue, with plans to increase this by INR 10-12 crores in FY27. The company is also pursuing EFSA/novel food approvals in Europe and pharma approvals in Asia, which are anticipated to drive faster growth in these international markets within the next 6-8 months.
Consistent Margin Profile and Long-Term Growth Outlook
Management reiterated its guidance for an EBITDA margin of 30-32% and a PAT margin of 21-22%, emphasizing that operational efficiency and product mix are key drivers for gross margin expansion. The growth achieved is considered long-term and sustainable, not reliant on one-off📎 factors. Despite being a relatively small player with less than 2% world market share, the company sees significant headroom for growth, supported by its R&D focus and diversified product portfolio.
High Inventory Levels and M&A Strategy
The company noted high inventory levels, partly attributed to a strategic build-up in anticipation of US tariffs. Advanced Enzyme holds approximately INR 600 crores in cash on its balance sheet. M&A remains a strategic focus, with the company actively evaluating targets in human nutrition (probiotics) and industrial bioprocessing, as well as pursuing forward integration opportunities in the animal feed business.